Sensodyne Fined Rs 10 Lakh by Consumer Body Over "Misleading Ads"
The Central Consumer Protection Authority (CCPA) has ordered discontinuation of certain misleading advertisements of Sensodyne toothpaste within seven days and imposed a penalty of Rs 10 lakh on the manufacturer.
An official release on Tuesday stated that advertisements of Sensodyne products which make the claims 'Recommended by dentists worldwide' and 'World's No.1 sensitivity toothpaste' have been ordered to be discontinued within seven days. The authority also directed payment of penalty of Rs 10 lakh.
Advertisements which show endorsements by foreign dentists have been ordered to be discontinued as per the earlier order passed by CCPA.
The CCPA, headed by Nidhi Khare, "recently passed order against misleading advertisements of Sensodyne products which make the claims 'Recommended by dentists worldwide' and 'World's No 1 sensitivity toothpaste," the statement said.
Previously on February 9, 2022, the CCPA had passed an order directing discontinuation of advertisement of Sensodyne products which show endorsement by foreign dentists.
The CCPA had initiated suo-moto action against advertisement of Sensodyne products on various platforms including television, Youtube, Facebook and Twitter. The advertisements show dentists practising outside India (United Kingdom) endorsing the use of Sensodyne products namely Sensodyne Rapid Relief and Sensodyne Fresh Gel for protection against teeth sensitivity.
These advertisements make claims that Sensodyne is 'Recommended by dentists worldwide', 'World's No. 1 sensitivity toothpaste' and 'clinically proven relief, works in 60 seconds', the statement said.
"After examination of the response submitted by the company, CCPA observed that the two market surveys submitted by the company in support of its claims 'Recommended by dentists worldwide' and 'World's No.1 sensitivity toothpaste' made in the advertisements were conducted only with dentists in India.
"No cogent study or material were submitted by the company to substantiate the claims made in the advertisements or indicate any worldwide prominence of Sensodyne products. Thus, the claims were observed to be bereft of any reason or justification," the ministry said.
With respect to the claim of 'clinically proven relief, works in 60 seconds', the CCPA had written to the Drugs Controller General of India, Central Drugs Standard Control Organisation (CDSCO) to furnish its comments on the correctness of the claims made by the company.
The CDSCO has directed The Assistant Drug Controller, Licensing Authority, Silvassa to investigate the claims made by the company since the product in question is manufactured under cosmetic license granted by State Licensing Authority, Silvassa.
The Assisting Drug Controller has written to the CCPA stating that the claims made by the company are under investigation and further action will be initiated after the hearing process.
"In view of the communication received from CDSCO and Assistant Drug Controller, Licensing Authority, Silvassa as regards the claim of 'clinically proven relief, works in 60 seconds', the matter now rests with Assistant Drug Controller, State Licensing Authority, Silvassa," the statement said.
Therefore, the CCPA has ordered discontinuation of advertisements of Sensodyne products which make the claims 'Recommended by dentists worldwide' and 'World's No.1 sensitivity toothpaste' within seven days and directed payment of penalty of Rs 10 lakh.
Also, advertisements which show endorsements by foreign dentists have been ordered to be discontinued as per the earlier order passed by CCPA, it added.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.